B-cell Depletion Therapy in Pediatric Neuroinflammatory Disease.
Publication Title
Current neurology and neuroscience reports
Document Type
Article
Publication Date
10-1-2024
Keywords
oregon; portland
Abstract
PURPOSE OF REVIEW: B-cell depletion therapy, including anti-CD20 and anti-CD19 therapies, is increasingly used for a variety of autoimmune and conditions, including those affecting the central nervous system. However, B-cell depletion therapy use can be complicated by adverse effects associated with administration and immunosuppression. This review aims to summarize the application of anti-CD20 and anti-CD19 therapies for the pediatric neurologist and neuroimmunologist.
RECENT FINDINGS: Most existing literature come from clinical trials with adult patients, although more recent studies are now capturing the effects of these therapies in children. The most common side effects include infusion related reactions and increased infection risk from immunosuppression. Several strategies can mitigate infusion related reactions. Increased infections due to persistent hypogammaglobulinemia can benefit from replacement immunoglobulin. B-cell depletion therapies can be safe and effective in pediatric patients. Anticipation and mitigation of common adverse effects through primary prevention strategies, close monitoring, and appropriate symptomatic management can improve safety and tolerability.
Clinical Institute
Neurosciences (Brain & Spine)
Clinical Institute
Women & Children
Specialty/Research Institute
Pediatrics
Specialty/Research Institute
Neurosciences
DOI
10.1227/neu.0000000000003042
